Manna Israel Corp. (OTC: MCI) is a company that produces marijuana for medicinal and recreational use. It holds licenses in both the UK (Cannabis Act 2016) and Israel (Cannabis Medical Law, 2016). The company is looking to list on the Nasdaq Global Market under the ticker MCI.
With Wall Street on board, Israeli company Caliber Medical is looking to take its marijuana-infused edible products to the U.S. Nasdaq is currently reviewing its listing application. The company says demand for its products is strong and it’s already sold cannabis-infused products to more than 10,000 consumers in Israel. Caliber is also currently licensed to operate in 12 countries, including Canada, Spain, Germany and South Korea. ~ ~ ~
Leading Isreali Marijuana Stock Ready for Nasdaq Listing The Isreali government has approved medical marijuana, a move that will pave the way for the country to become a leading economy for medical marijuana production in the world. The decision follows the implementation of the first ever regulations related to medical marijuana in the world, which were put in place in December, 2013. The move is the culmination of a four-year long process, during which Isreali citizens were allowed to grow medical marijuana on their private property in order to treat a wide range of medical conditions including cancer, AIDS, and epilepsy.. Read more about cbd stocks to watch and let us know what you think.
Will This Under-the-Radar Cannabis Stock Make It to the Major Leagues?
The most well-known marijuana stocks in North America are from either the United States or Canada. After all, Canada legalized recreational cannabis throughout the country in October 2018, while the United States’ changing regulatory climate has resulted in a slew of thriving cannabis businesses.
But there are millions of marijuana users outside of the United States and Canada, which is why I’d like to speak about InterCure Ltd, a little-known marijuana business (TSE:INCR.U, OTCMKTS:IRCLF).
Israel is the home of InterCure stock. Canndoc, the company’s fully owned subsidiary, is the country’s biggest legal cannabis producer and one of the first to provide GMP-certified and pharmaceutical-grade medical cannabis products.
Given its small population, Israel may not have piqued the interest of most marijuana investors, but it does have a thriving cannabis industry. In 2008, the nation authorized medicinal marijuana, increased medical marijuana usage, allowed medical marijuana exporting in 2019, and has a growing number of marijuana users.
Consider this: Israel has 32,000 medicinal cannabis patients in the first quarter of 2019. In the first quarter of 2020, the number increased to 59,000, and by the end of the year, it had risen to 77,000. (InterCure Ltd, January 26, 2021, “Dominating the Cannabis Industry in Israel.”)
And that’s only the beginning: by 2025, Israel is projected to have 250,000 medicinal cannabis patients, up from 120,000 this year. The medicinal marijuana industry in Israel is expected to increase from $214.0 million in 2020 to $562.0 million in 2024.
InterCure Ltd, it turns out, is presently Israel’s most lucrative cannabis business.
Of fact, when compared to marijuana stocks located in the United States and Canada, IRCLF stock is a fly-by-night operation. InterCure stock is traded on the Tel Aviv Stock Exchange under the ticker “INCR” and on the Toronto Stock Exchange under the ticker “INCR.U” at the time of writing.
The stock is now trading over-the-counter in the United States under the symbol “IRCLF.”
InterCure has filed to list its common shares on the Nasdaq Capital Market under the trading name “INCR,” which will change very shortly. InterCure stock is expected to begin trading on the Nasdaq in the final week of July, pending the fulfillment of certain criteria. (Source: InterCure Ltd, “InterCure Provides an Update on its NASDAQ Listing,” July 10, 2021.)
InterCure has been putting forth some excellent financial results.
The business achieved a total income of NIS65 million ($20.2 million) in 2020, a significant rise from the $3.0 million it made in 2019. (Source: InterCure Ltd, March 31, 2021, “Subversive Acquisition LP Highlights InterCure’s Accelerated Growth as the Leading Israeli Cannabis Company.”)
InterCure struck partnerships with a number of well-known marijuana businesses in 2020, including Tilray Inc (NASDAQ:TLRY), Aphria Inc (now part of Tilray), and OrganiGram Holdings Inc. (NASDAQ:OGI).
InterCure had a profit of NIS33.1 million ($10.3 million) in the first quarter of 2021. That was more than eight times what it made in the first quarter of 2020, and it was up more than 22% sequentially. (InterCure Ltd, May 17, 2021, “InterCure Announces Another Record-Breaking First Quarter Financial Results.”)
In the first quarter of 2021, InterCure earned NIS7.7 million ($2.4 million) in cash flow from operations. This was the third quarter in a row that the marijuana stock generated positive operational cash flow.
The present business trends are expected to continue in 2021, according to management.
To summarize, InterCure Ltd is a rapidly expanding Israeli marijuana business that has yet to attract many American investors. If the business is successful in getting its shares listed on the Nasdaq, it will increase its exposure and reach a far wider audience of investors.
IRCLF stock is a stock that savvy investors should start paying attention to right now.
This article broadly covered the following related topics:
- marijuana stocks list
- random 100 stocks
- stock market project worksheet
- stock market project example
- best marijuanas stocks 2021 reddit